Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0380Keywords:
Nemolizumab, atopic dermatitis, Prurigo nodularis, Patient-reported outcome, Daily topical treatment time, daily preoccupation timeDownloads
References
Pereira MP, Hoffmann V, Weisshaar E, Wallengren J, Halvorsen JA, Garcovich S, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol 2020; 34: 2373–2383. DOI: https://doi.org/10.1111/jdv.16309
Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol 2025; 193: 642–652. DOI: https://doi.org/10.1093/bjd/ljaf213
Igarashi A, Yoshida T, Sunaga Y, Nawata H, Arima K. Current status of prurigo nodularis in Japan: a retrospective study using a health insurance claims database. J Clin Med 2025; 14: 1872. DOI: https://doi.org/10.3390/jcm14061872
Waitek M, Weisshaar E. The epidemiology of chronic prurigo: lessons learned. Acta Derm Venereol 2025; 105: adv44334. DOI: https://doi.org/10.2340/actadv.v105.44334
Murota H, Matsumoto M, Arima K, Yoshida T, Fujita H. Current clinical practice of prurigo nodularis in Japan: a cross-sectional web-survey among dermatologists. J Dermatol 2025; 52: 348–352. DOI: https://doi.org/10.1111/1346-8138.17400
Murota H, Arima K, Yoshida T, Fujita H. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. J Dermatol 2024; 51: 223–233. DOI: https://doi.org/10.1111/1346-8138.17045
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180–1190. DOI: https://doi.org/10.1038/s41591-023-02320-9
Ständer S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A, et al. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36: 1820–1825. DOI: https://doi.org/10.1111/jdv.18377
Kwatra SG, Ständer S, Yosipovitch G, Kim BS, Levit NA, O’Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Invest Dermatol 2025; 145: 249–256. DOI: https://doi.org/10.1016/j.jid.2024.06.1276
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579–1589. DOI: https://doi.org/10.1056/NEJMoa2301333
Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol 2025.
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502–507. DOI: https://doi.org/10.2340/00015555-1246
Zeidler C, Pereira MP, Augustin M, Spellman M, Ständer S. Investigator’s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol 2021; 101: adv00401. DOI: https://doi.org/10.2340/00015555-3701
Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med 2025; 14: 3026. DOI: https://doi.org/10.3390/jcm14093026
Mima Y, Yamamoto M, Iozumi K. The absence of recent systemic therapy can be a significant risk factor for nemolizumab-associated cutaneous adverse events in patients with prurigo nodularis: a single-centre retrospective study. Acta Derm Venereol 2025; 105: adv44310. DOI: https://doi.org/10.2340/actadv.v105.44310
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
